Published by Iain Gilbert on 29th May 2026
(Sharecast News) - Drugmaker Astrazeneca said on Friday that Imfinzi has been approved in the US as part of the first immunotherapy‑based combination for patients with high‑risk, non‑muscle‑invasive bladder cancer who have not previously been treated with Bacillus Calmette-Guérin.
URL: http://www.digitallook.com/dl/news/story/35964941/...